Long-term clinical and economic benefits associated with the management of a nosocomial outbreak resulting from extended-spectrum beta-lactamase-producing Klebsiella pneumoniae

Piednoir E, Thibon P, Borderan GC, Godde F, Borgey F, Le Coutour X, Parienti JJ

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
21765349

DOI
10.1097/CCM.0b013e31822827e0

Original Paper URL
http://journals.lww.com/ccmjournal/pages/articleviewer.aspx?year=2011&amp;issue=12000&amp;article=00012&amp;amp;type=abstract

Indexing Status
Subject indexing assigned by NLM

MeSH
Anti-Bacterial Agents /therapeutic use; Cost-Benefit Analysis; Cross Infection /drug therapy /economics /prevention & control; Disease Outbreaks /economics /prevention & control; Female; Hospital Costs; Humans; Intensive Care Units /economics /statistics & numerical data; Klebsiella Infections /drug therapy /economics /prevention & control; Klebsiella pneumoniae /drug effects; Male; Middle Aged; beta-Lactam Resistance

AccessionNumber
22011002004

Date bibliographic record published
15/02/2012